• Amkor Technology, Inc., a U.S.-headquartered, global supplier of outsourced semiconductor interconnect services, in its joint venture and license agreements with Toshiba Corporation to provide semiconductor assembly and final testing services in Japan.
    • Bicycle Therapeutics in its US$424 million collaboration with Bioverativ, a recent Biogen spin-off, covering potential treatments for hemophilia and sickle cell disease using Bicycle’s bicyclic peptide platform.
    • Kymera Therapeutics in its up-to-US$2 billion multi-program, strategic collaboration with French pharmaceutical company Sanofi to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases. Dechert negotiated and drafted the very complex IP terms of the deal, including patent strategy and due diligence. 
    • Kyn Therapeutics on patent strategy and diligence in its global strategic collaboration with Celgene Corporation. 
    • Merck KGaA in a licensing agreement with Vertex Pharmaceuticals for the worldwide development and commercialization of four research and development programs for the treatment of cancer. As part of the agreement, Merck KGaA will license two clinical-stage programs targeting DNA damage and repair, along with two additional novel pre-clinical programs. Vertex will receive an upfront payment of US$230 million, in addition to royalties on future net sales. Merck KGaA will assume full responsibility for the development and commercialization of all the programs.
    • Nimbus Therapeutics in devising and implementing a patent portfolio strategy resulting in a strategic immunology alliance with Celgene Corporation to develop programs for patients with autoimmune disorders.
    • Padlock Therapeutics in an IP due diligence and negotiations with GlaxoSmithKline resulting in exclusive license to GSK’s proprietary PAD4 inhibitors to kick off Padlocks’ novel approach to treating inflammatory disorders. After Dechert developed and implemented Padlock’s internal patent strategy, the company was acquired by Bristol-Myers Squibb for US$600 million.
    • Royalty Pharma in performing IP due diligence in the sale of Ligand Pharmaceutical’s Promacta®-related intellectual property rights licensed to Novartis, including the royalty stream on worldwide net sales of Promacta® to Royalty Pharma for US$827 million in cash.
    • Multiple venture firms in IP diligences resulting in the creation of numerous new pharmaceutical and biotech companies.